A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis (NCT05076175)

🧪 Interventions in This Study

• Ozanimod (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (90 Sites)

Showing the first 25 of 90 sites.

• Local Institution - 0041 — Phoenix, Arizona
• University of Arizona — Tucson, Arizona
• Local Institution - 0052 — Garden Grove, California
• Loma Linda University Health System — Loma Linda, California
• Cedars-Sinai Medical Center — Los Angeles, California
• Lucile Packard Children's Hospital — Palo Alto, California
• University of California Davis Health — Sacramento, California
• Local Institution - 0007 — Hartford, Connecticut
• Local Institution - 0064 — Washington D.C., District of Columbia
• Local Institution - 0075 — Orlando, Florida
• Local Institution - 0016 — Atlanta, Georgia
• Local Institution - 0101 — Park Ridge, Illinois
• Local Institution - 0100 — Indianapolis, Indiana
• Local Institution - 0049 — Iowa City, Iowa
• Maine Medical Partners — Portland, Maine
• Boston Children's Hospital — Boston, Massachusetts
• Local Institution - 0042 — Springfield, Massachusetts
• University of Massachusetts Chan Medical School — Worcester, Massachusetts
• Local Institution - 0093 — Detroit, Michigan
• Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
• Washington University — St Louis, Missouri
• Local Institution - 0028 — New York, New York
• Columbia University Medical Center — New York, New York
• Local Institution - 0023 — New York, New York
• University of North Carolina Medical Center — Chapel Hill, North Carolina

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Colitis, Ulcerative

• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Oakland, California
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Arcadia, California
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Litchfield Park, Arizona
• Determination of the Optimal Treatment Target in Ulcerative Colitis — Ypsilanti, Michigan
• A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis — Kelowna, British Columbia
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — San Francisco, California

Explore by condition: All Colitis, Ulcerative clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.